口服抗凝药相关脑出血的危险因素与多病共存:关键试验与真实世界患者比较
基于丹麦首都地区401例口服抗凝药相关脑出血(OAC-ICH)患者队列,比较真实世界DOAC与VKA使用者及关键试验患者的危险因素与多病负担。真实世界DOAC与VKA使用者危险因素、CHADS2及Charlson共病指数相当,但DOAC使用者卒中前mRS更高、女性更多。真实世界患者较试验患者年龄更大、女性比例更高,CHADS2评分相当。
要点
- 真实世界DOAC-ICH与VKA-ICH患者危险因素和共病负担相似。
- DOAC使用者较VKA使用者卒中前mRS更高(中位1 vs 0,P=0.002)且女性更多(53% vs 39%,P=0.009)。
- 真实世界OAC-ICH患者较关键试验患者年龄更大、女性比例更高,CHADS2评分相当。
核心结论
- 真实世界DOAC-ICH与VKA-ICH患者危险因素和共病负担相似,真实世界与试验患者共病负担也相似。
- 真实世界患者尤其DOAC使用者较试验患者年龄更大且女性更多,提示心血管试验需纳入足够老年人和女性以保障安全数据。
研究设计与样本
- COOL-ICH队列纳入丹麦首都地区401例连续急性OAC-ICH患者,其中VKA-ICH 272例、DOAC-ICH 129例。
- 试验患者危险因素与患病情况取自已发表文献。
主要发现
- 真实世界DOAC与VKA使用者危险因素、CHADS2和Charlson共病指数相当。
- DOAC使用者卒中前mRS高于VKA使用者(中位1 vs 0,P=0.002),女性比例更高(53% vs 39%,P=0.009)。
- 真实世界患者较试验患者年龄更大、女性比例更高,CHADS2评分相当。
临床怎么用
- 对真实世界OAC-ICH患者应关注其较试验人群年龄更大、女性更多的特点,处方决策需考虑此差异。
- DOAC使用者卒中前功能状态(mRS)更高,提示需重视该亚组的功能评估与个体化抗凝管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We hypothesised that morbidity burden was higher in real-life patients with oral anticoagulant-related intracerebral haemorrhage (OAC-ICH) than direct oral anticoagulant (DOAC) trial-life patients (pivotal trial participants) and explored if pre-stroke morbidity was comparable (i) in real-life patients on DOAC or vitamin K antagonist (VKA) with ICH, and (ii) in trial-life patients versus real-life patients with OAC-ICH. METHODS: The COOL-ICH cohort included 401 acute, consecutive patients with OAC-ICH (272 VKA-ICH, 129 DOAC-ICH) from the Capital Region of Denmark. Risk-factors and morbidity in trial-life patients were retrieved from publications. RESULTS: Risk-factors, CHADS2 and Charlson Comorbidity Index were comparable in DOAC vs VKA users in real-life. Pre-stroke modified Rankin Scale (mRS) was higher in DOAC users than in VKA users (median mRS 1 vs 0, P = 0.002). More DOAC users were women (53% vs 39%, P = 0.009). Compared to trial-life patients, age and proportion of women were higher in real-life patients. CHADS2-scores were comparable. CONCLUSION: In conclusion, burden of risk-factors and comorbidities were similar in real-life patients with DOAC-ICH and VKA-ICH, as well as in real-life patients compared to trial-life patients. However, real-life patients especially those on DOAC, were older and more frequently women than trial-life patients. It is reassuring that burden of comorbidity was similar in real-life and trial-life patients. Nevertheless, this report underlines the importance of recruiting adequate numbers of older people and women to cardio-vascular trials to ensure sufficient safety data to advice prescriptions in these very prevalent sub-groups of patients.
引用
- Grundtvig J, Gaist D, Christensen L, et al. Risk-factors and multimorbidity in oral anticoagulant-related intracerebral haemorrhage: a comparison of patients in pivotal trials and real life. Age Ageing. 2025. PMID: 40237713. doi:10.1093/ageing/afaf091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。